Profound Medical Reports New Statistically Significant Tulsa Trial Results; Shares Rise

MT Newswires Live07-25

Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.

At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.

The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.

Profound Medical shares rose 3.4% in Friday trading.

Price: 7.08, Change: +0.23, Percent Change: +3.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654039980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-25 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654039980","market":"sh","top_or_hot":-1,"title":"Profound Medical Reports New Statistically Significant Tulsa Trial Results; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.</p><p>At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.</p><p>The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.</p><p>Profound Medical shares rose 3.4% in Friday trading.</p><p>Price: 7.08, Change: +0.23, Percent Change: +3.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Profound Medical Reports New Statistically Significant Tulsa Trial Results; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProfound Medical Reports New Statistically Significant Tulsa Trial Results; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-25 01:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.</p><p>At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.</p><p>The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.</p><p>Profound Medical shares rose 3.4% in Friday trading.</p><p>Price: 7.08, Change: +0.23, Percent Change: +3.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PROF","symbol_name":"Profound Medical Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654039980","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654039980","pubTimestamp":1784913522,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Profound Medical  said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.Profound Medical shares rose 3.4% in Friday trading.Price: 7.08, Change: +0.23, Percent Change: +3.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PROF":"Profound Medical Corp.","BK4082":"医疗保健设备"},"translate_title":"Profound Medical 报告了新的具有统计学意义的塔尔萨试验结果；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PROF":1},"content_text":"Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.Profound Medical shares rose 3.4% in Friday trading.Price: 7.08, Change: +0.23, Percent Change: +3.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654039980","isCrawlerRequest":true}